World's Best Scientists 2026 revealed!
Award Badge
Microbiology
Argentina
2026

D-Index & Metrics

Microbiology

D-Index
66
Citations
19480
World Ranking
2361
National Ranking
1

Research.com Recognitions

  • 2026 - Research.com Microbiology in Argentina Leader Award
  • 2025 - Research.com Microbiology in Argentina Leader Award

Overview

Pedro Cahn is affiliated with the University of Buenos Aires in Argentina. Their research primarily focuses on the field of Medicine, with a strong emphasis on Infectious Diseases, Virology, Epidemiology, Emergency Medicine, and Public Health, Environmental and Occupational Health.

The scientist has contributed extensively to several main topics of work, including:

  • HIV/AIDS Research and Interventions
  • HIV/AIDS drug development and treatment
  • HIV Research and Treatment
  • HIV-related health complications and treatments
  • HIV, Drug Use, Sexual Risk
  • SARS-CoV-2 and COVID-19 Research
  • LGBTQ Health, Identity, and Policy

Pedro Cahn has published numerous papers in notable journals. Some of the recent publications include:

  • "Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression" (2020) in New England Journal of Medicine
  • "Mpox in people with advanced HIV infection: a global case series" (2023) in The Lancet
  • "Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial" (2021) in The Lancet
  • "Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection" (2020) in New England Journal of Medicine
  • "Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV" (2021) in Nature Communications

Frequent co-authors who have collaborated with Pedro Cahn include:

  • Omar Sued
  • María Inés Figueroa
  • María José Rolón
  • Jean-Michel Molina
  • Diego Cecchini

The scientist's research has appeared most frequently in the following publication venues:

  • Actualizaciones en Sida e Infectología
  • The Lancet HIV
  • SSRN Electronic Journal
  • New England Journal of Medicine
  • UNC Libraries

Best Publications

  • Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study

    Daniel D. Murray;Kazuo Suzuki;Matthew Law;Jonel Trebicka

  • Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society–USA Panel

    Huldrych F Gunthard;Judith A Aberg;Joseph J Eron;Jennifer Frances Hoy

  • Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

    F van Leth;P Phanuphak;K Ruxrungtham;E Baraldi

  • Antiretroviral Treatment of Adult HIV Infection

    Scott M. Hammer;Joseph J. Eron;Peter Reiss;Robert T. Schooley

  • Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

    Adriano Lazzarin;Thomas Campbell;Bonaventura Clotet;Margaret Johnson

  • Antiretroviral Treatment of Adult HIV Infection

    Unknown

  • Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial

    Jean Michel Molina;Pedro Cahn;Beatriz Grinsztejn;Adriano Lazzarin

  • Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.

    Unknown

  • Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

    Susan Swindells;Jaime-Federico Andrade-Villanueva;Gary J. Richmond;Giuliano Rizzardini

  • Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

    Pedro Cahn;Anton L Pozniak;Horacio Mingrone;Andrey Shuldyakov

  • Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

    Charles B Hicks;Pedro Cahn;David A Cooper;Sharon L Walmsley

  • Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

    Unknown

  • Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration

    Rami Kantor;David A Katzenstein;Brad Efron;Ana Patricia Carvalho

  • Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

    Unknown

  • Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.

    Frank van Leth;Prahpan Phanuphak;Erik Stroes;Brian Gazzard

  • Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results.

    Robert Leo Murphy;Ian Sanne;Pedro Cahn;Praphan Phanuphak

  • Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

    Pedro Cahn;Juan Sierra Madero;José R Arribas;Andrea Antinori

  • Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials

    Calvin J. Cohen;Jean-Michel Molina;Pedro Cahn;Bonaventura Clotet

  • Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.

    Xavier Saez-Llorens;Avyi Violari;Carl O. Deetz;Richard A. Rode

  • Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial.

    Michael S. Saag;Pedro Cahn;François Raffi;Marcelo Wolff

  • Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial

    Pedro Cahn;Jaime Andrade-Villanueva;José R Arribas;José M Gatell

  • A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).

    Daniel Podzamczer;Elena Ferrer;Ezequiel Consiglio;José Maria Gatell

  • G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate.

    Laura Rodero;Emilia Mellado;A Carolina Rodriguez;Angela Salve

  • Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme

    Catherine C McGowan;Pedro Cahn;Eduardo Gotuzzo;Denis Padgett

  • Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.

    Ulrik B.Ulrik Dragsted;Jan Gerstoft;Court Pedersen;Barry Peters

  • Discontinuation of Maintenance Therapy for Cryptococcal Meningitis in Patients with AIDS Treated with Highly Active Antiretroviral Therapy: An International Observational Study

    Cristina Mussini;Patrizio Pezzotti;José M. Miró;Esteban Martinez

Frequent Co-Authors

Beatriz Grinsztejn
Beatriz Grinsztejn Oswaldo Cruz Foundation
Julio S. G. Montaner
Julio S. G. Montaner University of British Columbia
Jean-Michel Molina
Jean-Michel Molina Université Paris Cité
Sharon Walmsley
Sharon Walmsley University Health Network
Margaret Johnson
Margaret Johnson The Royal Free Hospital
Eduardo Gotuzzo
Eduardo Gotuzzo Instituto de Medicina Tropical Alexander von Humboldt
Anne-Mieke Vandamme
Anne-Mieke Vandamme Rega Institute for Medical Research
Jose R. Arribas
Jose R. Arribas Hospital Universitario La Paz
José M. Gatell
José M. Gatell University of Barcelona
Lynn Morris
Lynn Morris University of the Witwatersrand

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Microbiology in the USA opens doors to a variety of career paths, many of which can be pursued through related online degrees. For those with unique challenges, options like degrees for felons provide accessible educational opportunities tailored to diverse backgrounds.

Healthcare roles linked to microbiology, such as becoming a functional medicine nurse practitioner, combine specialized knowledge of pathogens with patient care. Online programs supporting such careers enable students to gain essential skills remotely, balancing education with real-world demands.

Beyond clinical roles, microbiology graduates may explore allied areas like medical coding and health data management. Certified Professional Coders enjoy competitive salaries, as highlighted under cpc salary insights, making certification a valuable complement to scientific expertise.

Additionally, a health information management bachelor degree salary reflects the strong earning potential in managing health data systems, crucial to modern microbiology research and healthcare services.

Best Scientists Citing Pedro Cahn

Trending Scientists

Recently Published Articles